Skinovation Pharmaceutical Inc financial data

Industry
Blank Checks
Location
440 East 400 South, Ste 300, Salt Lake City, UT
State of incorporation
WY
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 21, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.9 % +78.1%
Debt-to-equity -102 % -0.85%
Return On Equity 9.65 % +18.3%
Return On Assets -499 % +34.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 708K shares
Common Stock, Shares, Outstanding 708K shares 0%
Entity Public Float 0 USD
Common Stock, Value, Issued 708 USD 0%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 22.3K USD +55.5%
Operating Income (Loss) -22.3K USD -55.5%
Net Income (Loss) Attributable to Parent -45K USD -29.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.84K USD -80.9%
Assets, Current 1.84K USD -80.9%
Assets 1.84K USD -80.9%
Accounts Payable, Current 10.5K USD 0%
Liabilities, Current 485K USD +8.31%
Liabilities 485K USD +8.31%
Retained Earnings (Accumulated Deficit) -509K USD -9.7%
Stockholders' Equity Attributable to Parent -483K USD -10.3%
Liabilities and Equity 1.84K USD -80.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.5K USD +17.1%
Net Cash Provided by (Used in) Financing Activities 9K USD +80%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 708K shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.5K USD -173%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.84K USD -80.9%
Deferred Tax Assets, Valuation Allowance 99.3K USD +8.2%
Deferred Tax Assets, Operating Loss Carryforwards 99.3K USD +8.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Additional Paid in Capital 25.1K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Interest Expense 22.7K USD +11.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%